On track to file a Clinical Trial Application (CTA) by year end 2025, with initial clinical data expected mid-2026Important ...
This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...
ROTTERDAM, the Netherlands, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Pan Cancer T B.V., a biotech company pioneering next-generation T cell therapies for solid tumours, today announced a EUR 10 million ...
Automated TCR-T production streamlines personalized immunotherapy, reducing patient burden and improving engineered T cell quality.
Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a ...
STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback